

Human Papillomavirus (HPV) Vaccines Session

**Allison Kempe, MD, MPH
Chair, ACIP HPV Vaccines Work Group**

**Advisory Committee on Immunization Practices
October 21, 2015**

9-valent HPV vaccine

- ❑ Licensed by FDA in December 2014
- ❑ Recommended by ACIP at February 2015 meeting
 - MMWR Policy Note published on March 27, 2015

9-valent HPV vaccine for persons who completed an HPV vaccination series

❑ February 2015 ACIP meeting

- Abbreviated meeting
- Additional 9-valent HPV vaccination not discussed
- ACIP voted on 9-valent HPV vaccine recommendations

❑ June 2015 ACIP meeting

- ACIP HPV Vaccines WG reviewed additional 9-valent HPV vaccination
 - Burden of disease, immunogenicity study, cost effectiveness
 - Q&A to be posted on CDC website
- Discussion about consideration of review again using GRADE
- After meeting, Q&A posted with announcement in MMWR (July 2015)

Q&As posted on CDC website

Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV vaccine

A 9-valent human papillomavirus (HPV) vaccine (Gardasil 9, Merck & Co., Inc) was licensed for use in females and males in the United States in December 2014.^{1,2,3,4} 9-valent HPV vaccine is the third HPV vaccine licensed by the

Links from ACIP website

<http://www.cdc.gov/vaccines/acip/index.htm>

<http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html>

Announcement in MMWR 2015;64

Announcement

Additional Guidance Online for Providers Regarding 9-Valent HPV Vaccine Use Among Persons Who Previously Received HPV Vaccination

A 9-valent human papillomavirus (HPV) vaccine (Gardasil 9, Merck and Co., Inc.) was licensed for use in females and males in the United States in December 2014 (1,2). This is the third HPV vaccine licensed by the Food and Drug Administration;

9-valent HPV Vaccine

Additional guidance

 [4 pages] for providers regarding 9-vHPV vaccine use among persons who previously received 2vHPV or 4vHPV vaccine.



“There is no ACIP recommendation for routine additional 9-valent HPV vaccination of persons who previously completed a quadrivalent or bivalent vaccination series.”

ACIP HPV Vaccines Work Group

- ❑ Re-discussed 9-valent HPV vaccine for persons who completed an HPV vaccination series
- ❑ Talked with other professional groups (AAP, SAHM, COID)
- ❑ Reviewed additional transition issues
- ❑ Almost all members felt we should not bring back to ACIP at this meeting

Outline of October 2015 HPV session

- Introduction

Dr. Allison Kempe, Chair

- HPV vaccination coverage in the US, NIS-Teen 2014

Dr. Sarah Reagan-Steiner, NCIRD

- Programmatic strategies to increase HPV vaccine coverage

Dr. C. Robinette Curtis, NCIRD

- Update on HPV vaccine safety

Dr. Lakshmi Sukumaran, NCEZID

- Monitoring impact of the HPV vaccination program and future Workgroup plans

Dr. Lauri Markowitz, NCHHSTP

ACIP HPV Vaccines Work Group members

ACIP Members

Allison Kempe (Chair)
Laura Riley
Jose Romero

Ex Officio Members

Carolyn Deal (NIH)
Bruce Gellin (NVPO)
Jeff Roberts (FDA)
Sixun Yang (FDA)

CDC Lead

Lauri Markowitz

Liaison Representatives

Shelley Deeks (NACCI)
Linda Eckert (ACOG)
Sandra Fryhofer (ACP)
Amy Middleman (SAHM)
Chris Nyquist (AAP)
Margo Savoy (AAFP)
Patricia Whitley-Williams (NMA)
Jane Zucker (AIM)

Consultants

Joseph Bocchini
Tamera Coyne-Beasley
John Douglas
Janet Englund
Sam Katz
Aimee Kreimer (NCI)
Debbie Saslow (ACS)
Rodney Willoughby